New Funding for MGB Biopharma to Complete Clinical Trial

MGB Biopharmaa biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, has announced the completion of its latest funding round. The over-subscribed fund-raise was supported by new and existing investors, led by Archangel Investors and including Scottish Investment Bank (the investment arm of Scottish Enterprise, Scotland’s national economic development agency), Barwell and TriCapital Investors.

The new funding will allow the company to complete all activities around its ongoing Phase IIa clinical trial with its lead antibiotic MGB-BP-3 and prepare for the next stages of its development and to progress other programmes through to H2 2020.

Read more HERE and HERE.